Genetically Engineered Mouse Models of Melanoma

Overview

Journal Cancer

Publisher Wiley

Specialty Oncology

Date 2017 May 26

PMID 28543694

Citations 39

Authors

Eva Perez-Guijarro

Chi-Ping Day

Glenn Merlino

M Raza Zaidi

Affiliations

Soon will be listed here.

Abstract

Melanoma is a complex disease that exhibits highly heterogeneous etiological, histopathological, and genetic features, as well as therapeutic responses. Genetically engineered mouse (GEM) models provide powerful tools to unravel the molecular mechanisms critical for melanoma development and drug resistance. Here, we expound briefly the basis of the mouse modeling design, the available technology for genetic engineering, and the aspects influencing the use of GEMs to model melanoma. Furthermore, we describe in detail the currently available GEM models of melanoma. Cancer 2017;123:2089-103. © 2017 American Cancer Society.

Citing Articles

Transcriptional reprogramming triggered by neonatal UV radiation or Lkb1 loss prevents BRAF-induced growth arrest in melanocytes.

McGrail K, Granado-Martinez P, Orsenigo R, Caratu G, Nieto P, Heyn H Oncogene. 2025; .

PMID: 40057604 DOI: 10.1038/s41388-025-03339-7.

Generation of a genetically engineered porcine melanoma model featuring oncogenic control through conditional Cre recombination.

Oh D, Hong N, Eun K, Lee J, Cai L, Kim M Sci Rep. 2025; 15(1):1616.

PMID: 39794352 PMC: 11724099. DOI: 10.1038/s41598-024-82554-w.

Aspects and prospects of preclinical theranostic radiopharmaceutical development.

Nelson B, Krol V, Bansal A, Andersson J, Wuest F, Pandey M Theranostics. 2024; 14(17):6446-6470.

PMID: 39479448 PMC: 11519794. DOI: 10.7150/thno.100339.

Dangerous liaisons: Loss of keratinocyte control over melanocytes in melanomagenesis.

Green K, Pokorny J, Jarrell B Bioessays. 2024; 46(11):e2400135.

PMID: 39233509 PMC: 11626500. DOI: 10.1002/bies.202400135.

Orthotopic model for the analysis of melanoma circulating tumor cells.

Pickova M, Kahounova Z, Radaszkiewicz T, Prochazkova J, Fedr R, Noskova M Sci Rep. 2024; 14(1):7827.

PMID: 38570556 PMC: 10991390. DOI: 10.1038/s41598-024-58236-y.

References

Simon J, Peles D, Wakamatsu K, Ito S . Current challenges in understanding melanogenesis: bridging chemistry, biological control, morphology, and function. Pigment Cell Melanoma Res. 2009; 22(5):563-79. DOI: 10.1111/j.1755-148X.2009.00610.x. View

Sharpless N, Kannan K, Xu J, Bosenberg M, Chin L . Both products of the mouse Ink4a/Arf locus suppress melanoma formation in vivo. Oncogene. 2003; 22(32):5055-9. DOI: 10.1038/sj.onc.1206809. View

Nagy A . Cre recombinase: the universal reagent for genome tailoring. Genesis. 2000; 26(2):99-109. View

McKinney A, Holmen S . Animal models of melanoma: a somatic cell gene delivery mouse model allows rapid evaluation of genes implicated in human melanoma. Chin J Cancer. 2011; 30(3):153-62. PMC: 4013311. DOI: 10.5732/cjc.011.10007. View

Lin J, Fisher D . Melanocyte biology and skin pigmentation. Nature. 2007; 445(7130):843-50. DOI: 10.1038/nature05660. View

Tormo D, Ferrer A, Gaffal E, Wenzel J, Basner-Tschakarjan E, Steitz J . Rapid growth of invasive metastatic melanoma in carcinogen-treated hepatocyte growth factor/scatter factor-transgenic mice carrying an oncogenic CDK4 mutation. Am J Pathol. 2006; 169(2):665-72. PMC: 1698803. DOI: 10.2353/ajpath.2006.060017. View

Feng X, Degese M, Iglesias-Bartolome R, Vaque J, Molinolo A, Rodrigues M . Hippo-independent activation of YAP by the GNAQ uveal melanoma oncogene through a trio-regulated rho GTPase signaling circuitry. Cancer Cell. 2014; 25(6):831-45. PMC: 4074519. DOI: 10.1016/j.ccr.2014.04.016. View

Stott F, Bates S, James M, McConnell B, Starborg M, Brookes S . The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2. EMBO J. 1998; 17(17):5001-14. PMC: 1170828. DOI: 10.1093/emboj/17.17.5001. View

Sotillo R, Garcia J, Ortega S, Martin J, Dubus P, Barbacid M . Invasive melanoma in Cdk4-targeted mice. Proc Natl Acad Sci U S A. 2001; 98(23):13312-7. PMC: 60867. DOI: 10.1073/pnas.241338598. View

10.

Birck A, Ahrenkiel V, Zeuthen J, HOU-JENSEN K, Guldberg P . Mutation and allelic loss of the PTEN/MMAC1 gene in primary and metastatic melanoma biopsies. J Invest Dermatol. 2000; 114(2):277-80. DOI: 10.1046/j.1523-1747.2000.00877.x. View

11.

VanBrocklin M, Robinson J, Lastwika K, Khoury J, Holmen S . Targeted delivery of NRASQ61R and Cre-recombinase to post-natal melanocytes induces melanoma in Ink4a/Arflox/lox mice. Pigment Cell Melanoma Res. 2010; 23(4):531-41. PMC: 2906690. DOI: 10.1111/j.1755-148X.2010.00717.x. View

12.

Mitra D, Luo X, Morgan A, Wang J, Hoang M, Lo J . An ultraviolet-radiation-independent pathway to melanoma carcinogenesis in the red hair/fair skin background. Nature. 2012; 491(7424):449-53. PMC: 3521494. DOI: 10.1038/nature11624. View

13.

Le Y, Sauer B . Conditional gene knockout using cre recombinase. Methods Mol Biol. 2000; 136:477-85. DOI: 10.1385/1-59259-065-9:477. View

14.

Feil R, Brocard J, Mascrez B, Lemeur M, Metzger D, Chambon P . Ligand-activated site-specific recombination in mice. Proc Natl Acad Sci U S A. 1996; 93(20):10887-90. PMC: 38252. DOI: 10.1073/pnas.93.20.10887. View

15.

Kwong L, Costello J, Liu H, Jiang S, Helms T, Langsdorf A . Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma. Nat Med. 2012; 18(10):1503-10. PMC: 3777533. DOI: 10.1038/nm.2941. View

16.

Bosenberg M, Muthusamy V, Curley D, Wang Z, Hobbs C, Nelson B . Characterization of melanocyte-specific inducible Cre recombinase transgenic mice. Genesis. 2006; 44(5):262-7. DOI: 10.1002/dvg.20205. View

17.

Damsky W, Micevic G, Meeth K, Muthusamy V, Curley D, Santhanakrishnan M . mTORC1 activation blocks BrafV600E-induced growth arrest but is insufficient for melanoma formation. Cancer Cell. 2015; 27(1):41-56. PMC: 4295062. DOI: 10.1016/j.ccell.2014.11.014. View

18.

Adams J, Cory S . Transgenic models of tumor development. Science. 1991; 254(5035):1161-7. DOI: 10.1126/science.1957168. View

19.

Indra A, Warot X, Brocard J, Bornert J, Xiao J, Chambon P . Temporally-controlled site-specific mutagenesis in the basal layer of the epidermis: comparison of the recombinase activity of the tamoxifen-inducible Cre-ER(T) and Cre-ER(T2) recombinases. Nucleic Acids Res. 1999; 27(22):4324-7. PMC: 148712. DOI: 10.1093/nar/27.22.4324. View

20.

Kato M, Takahashi M, Akhand A, Liu W, Dai Y, Shimizu S . Transgenic mouse model for skin malignant melanoma. Oncogene. 1998; 17(14):1885-8. DOI: 10.1038/sj.onc.1202077. View